Global Breast Cancer Therapeutics Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Breast Cancer Therapeutics Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Medicines include tamoxifen (Nolvadex) for women before and after menopause and aromatase inhibitors including anastrozole (Arimidex), exemestane (Aromasin), and letrozole (Femara) for postmenopausal women. Side effects can include hot flashes and vaginal dryness
Breast Cancer Therapeutics Drugs report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Breast Cancer Therapeutics Drugs market is projected to reach US$ 46070 million in 2033, increasing from US$ 26510 million in 2022, with the CAGR of 8.2% during the period of 2023 to 2033. Demand from Phase I and Phase II are the major drivers for the industry.
Breast cancer is the most common malignant tumor in the global female population, and data released by the International Agency for Research on Cancer (IARC) in 2020 show that about 2.26 million women will be diagnosed with breast cancer in 2020, surpassing the number of lung cancer diagnoses of 2.21 million for the first time, becoming the "number one cancer in the world." In China, the burden of breast cancer is no less heavy, and with the amplified effect of population ageing, the burden of disease in the female population is likely to increase further without sustained and effective intervention.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Breast Cancer Therapeutics Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Bayer HealthCare
Eli Lily
Pfizer
Novartis
Eisai
Halozyme Therapeutics
Roche
Puma Biotechnology
Janssen Biotech
AbbVie
BioMarin
Array BioPharma
Merck
Syndax
MacroGenics
ImmunoGen
Santen Pharma
Celgene
Oncothyreon
AstraZeneca
Sprint Bioscience
Genentech
Galena Biopharma
Lycera
CTI BioPharma
Segment by Type
Mitotic Inhibitors
Anti-Metabolites
Hormone Receptor
Aromatase Inhibitors
HER2 Inhibitors
Phase I
Phase II
Phase III
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Breast Cancer Therapeutics Drugs market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Breast Cancer Therapeutics Drugs introduction, etc. Breast Cancer Therapeutics Drugs Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Breast Cancer Therapeutics Drugs market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
Breast Cancer Therapeutics Drugs report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Breast Cancer Therapeutics Drugs market is projected to reach US$ 46070 million in 2033, increasing from US$ 26510 million in 2022, with the CAGR of 8.2% during the period of 2023 to 2033. Demand from Phase I and Phase II are the major drivers for the industry.
Breast cancer is the most common malignant tumor in the global female population, and data released by the International Agency for Research on Cancer (IARC) in 2020 show that about 2.26 million women will be diagnosed with breast cancer in 2020, surpassing the number of lung cancer diagnoses of 2.21 million for the first time, becoming the "number one cancer in the world." In China, the burden of breast cancer is no less heavy, and with the amplified effect of population ageing, the burden of disease in the female population is likely to increase further without sustained and effective intervention.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Breast Cancer Therapeutics Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Bayer HealthCare
Eli Lily
Pfizer
Novartis
Eisai
Halozyme Therapeutics
Roche
Puma Biotechnology
Janssen Biotech
AbbVie
BioMarin
Array BioPharma
Merck
Syndax
MacroGenics
ImmunoGen
Santen Pharma
Celgene
Oncothyreon
AstraZeneca
Sprint Bioscience
Genentech
Galena Biopharma
Lycera
CTI BioPharma
Segment by Type
Mitotic Inhibitors
Anti-Metabolites
Hormone Receptor
Aromatase Inhibitors
HER2 Inhibitors
Segment by Application
Phase I
Phase II
Phase III
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Breast Cancer Therapeutics Drugs market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Breast Cancer Therapeutics Drugs introduction, etc. Breast Cancer Therapeutics Drugs Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Breast Cancer Therapeutics Drugs market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices